-
Product Insights
Venous Thromboembolism – Drugs In Development, 2023
Global Markets Direct’s, ‘Venous Thromboembolism - Drugs In Development, 2023’, provides an overview of the Venous Thromboembolism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Venous Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Thrombosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Thrombosis - Drugs In Development, 2023’, provides an overview of the Thrombosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Ischemic Stroke – Drugs In Development, 2023
Global Markets Direct’s, ‘Ischemic Stroke - Drugs In Development, 2023’, provides an overview of the Ischemic Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Ovarian Cancer Drug Details: IPI-549 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varoglutamstat in Mild Cognitive Impairment
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Varoglutamstat in Mild Cognitive ImpairmentDrug Details:PQ-912 is under development for the treatment of early stage mild...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRL-1049 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRL-1049 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NRL-1049 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous...
-
Sector Analysis
Atrial Fibrillation Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032
Atrial Fibrillation Market Report Overview The AF market size across the 8MM was valued at $14.53 billion in 2022 and will decline at a CAGR of more than 1% during 2022-2032. However, the launch of a total of 5 products, including four anticoagulants and one cardioversion agent each of which will have a higher annual cost of therapy (ACOT) when compared with the cost of generic NOACs and the commonly used pharmacological agents respectively will drive market growth during the...
-
Sector Analysis
Venous Thromboembolism Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032
Venous Thromboembolism Market Report Overview Venous thromboembolism market size across the 7MM was valued at $3.57 billion in 2022 and will achieve a CAGR of more than 2% during 2022-2032. The market growth can be attributed to the large size of the VTE patient population in the US as well as the higher overall price of drugs as compared to the 5EU and Japan. Venous Thromboembolism Market Outlook, 2022-2032 ($ Billion) Buy Full Report to Get More Insights into the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – abelacimab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry abelacimab Drug Details Abelacimab is under development for the prevention of arterial and venous...